Two new clinical trials are set to begin at Griffith University’s Clinical Trial Unit (CTU) on the Gold Coast, as the Australian Government rolls out a new program to assist smaller companies and researchers to navigate complex regulations, in order to develop the next generation of medical devices, apps and therapeutic drugs.
With cold and flu season in full swing, the trials of innovative new diagnostic devices offer the promise of faster detection and treatment of bacterial and viral infections.
The trials will test in vitro diagnostic devices being commercialised by Brisbane company Ellume, and add to several drug treatment studies currently underway at the CTU, a state-of-the-art, core research facility for phase I-IV clinical trials.
Viral or bacterial?
CTU Director, Griffith University Associate Professor Evelin Tiralongo, said both Ellume trials are testing devices that may help to identify whether people are suffering from a viral or bacterial infection.
“One Ellume trial is looking to
Skip to content
News and other stories about real people, places, and events in Mount Gravatt and nearby suburbs.